• Immuneering presented the design of its ongoing Phase 3 MAPKeeper 301 trial at ESMO on Oct. 25, 2026.
• The trial tests atebimetinib with modified gemcitabine/nab-paclitaxel against standard chemotherapy as first-line treatment for metastatic pancreatic cancer.
• Overall survival is the primary endpoint; the study aims to determine whether the combination extends survival compared with standard treatment.
• Phase 2a results presented at ASCO in June 2026 showed encouraging survival outcomes, but comparisons with historical chemotherapy outcomes were not head-to-head.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260730PRIMZONEFULLFEED9852345) on October 26, 2026, and is solely responsible for the information contained therein.